492 related articles for article (PubMed ID: 15694309)
1. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma.
Patton EE; Widlund HR; Kutok JL; Kopani KR; Amatruda JF; Murphey RD; Berghmans S; Mayhall EA; Traver D; Fletcher CD; Aster JC; Granter SR; Look AT; Lee C; Fisher DE; Zon LI
Curr Biol; 2005 Feb; 15(3):249-54. PubMed ID: 15694309
[TBL] [Abstract][Full Text] [Related]
2. KIT Suppresses BRAF
Neiswender JV; Kortum RL; Bourque C; Kasheta M; Zon LI; Morrison DK; Ceol CJ
Cancer Res; 2017 Nov; 77(21):5820-5830. PubMed ID: 28947418
[TBL] [Abstract][Full Text] [Related]
3. BRAF
McNeal AS; Belote RL; Zeng H; Urquijo M; Barker K; Torres R; Curtin M; Shain AH; Andtbacka RH; Holmen S; Lum DH; McCalmont TH; VanBrocklin MW; Grossman D; Wei ML; Lang UE; Judson-Torres RL
Elife; 2021 Nov; 10():. PubMed ID: 34812139
[TBL] [Abstract][Full Text] [Related]
4. CDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma.
McNeal AS; Liu K; Nakhate V; Natale CA; Duperret EK; Capell BC; Dentchev T; Berger SL; Herlyn M; Seykora JT; Ridky TW
Cancer Discov; 2015 Oct; 5(10):1072-85. PubMed ID: 26183406
[TBL] [Abstract][Full Text] [Related]
5. Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice.
Goel VK; Ibrahim N; Jiang G; Singhal M; Fee S; Flotte T; Westmoreland S; Haluska FS; Hinds PW; Haluska FG
Oncogene; 2009 Jun; 28(23):2289-98. PubMed ID: 19398955
[TBL] [Abstract][Full Text] [Related]
6. Dynamics of nevus development implicate cell cooperation in the growth arrest of transformed melanocytes.
Ruiz-Vega R; Chen CF; Razzak E; Vasudeva P; Krasieva TB; Shiu J; Caldwell MG; Yan H; Lowengrub J; Ganesan AK; Lander AD
Elife; 2020 Oct; 9():. PubMed ID: 33047672
[TBL] [Abstract][Full Text] [Related]
7. Detection of the BRAF V600E mutation in melanocytic lesions using the ligase detection reaction.
Turner DJ; Zirvi MA; Barany F; Elenitsas R; Seykora J
J Cutan Pathol; 2005 May; 32(5):334-9. PubMed ID: 15811117
[TBL] [Abstract][Full Text] [Related]
8. The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes.
Yu H; McDaid R; Lee J; Possik P; Li L; Kumar SM; Elder DE; Van Belle P; Gimotty P; Guerra M; Hammond R; Nathanson KL; Dalla Palma M; Herlyn M; Xu X
Am J Pathol; 2009 Jun; 174(6):2367-77. PubMed ID: 19389934
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of the Hippo tumor suppressor pathway promotes melanoma.
Vittoria MA; Kingston N; Kotynkova K; Xia E; Hong R; Huang L; McDonald S; Tilston-Lunel A; Darp R; Campbell JD; Lang D; Xu X; Ceol CJ; Varelas X; Ganem NJ
Nat Commun; 2022 Jun; 13(1):3732. PubMed ID: 35768444
[TBL] [Abstract][Full Text] [Related]
10. Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53.
Viros A; Sanchez-Laorden B; Pedersen M; Furney SJ; Rae J; Hogan K; Ejiama S; Girotti MR; Cook M; Dhomen N; Marais R
Nature; 2014 Jul; 511(7510):478-482. PubMed ID: 24919155
[TBL] [Abstract][Full Text] [Related]
11. BRAF and NRAS mutations in melanoma and melanocytic nevi.
Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
[TBL] [Abstract][Full Text] [Related]
12. Deciphering the Role of Oncogenic MITFE318K in Senescence Delay and Melanoma Progression.
Bonet C; Luciani F; Ottavi JF; Leclerc J; Jouenne FM; Boncompagni M; Bille K; Hofman V; Bossis G; Marco de Donatis G; Strub T; Cheli Y; Ohanna M; Luciano F; Marchetti S; Rocchi S; Birling MC; Avril MF; Poulalhon N; Luc T; Hofman P; Lacour JP; Davidson I; Bressac-de Paillerets B; Ballotti R; Marine JC; Bertolotto C
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376192
[TBL] [Abstract][Full Text] [Related]
13. C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells.
Zhuang D; Mannava S; Grachtchouk V; Tang WH; Patil S; Wawrzyniak JA; Berman AE; Giordano TJ; Prochownik EV; Soengas MS; Nikiforov MA
Oncogene; 2008 Nov; 27(52):6623-34. PubMed ID: 18679422
[TBL] [Abstract][Full Text] [Related]
14. Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis.
Wu J; Rosenbaum E; Begum S; Westra WH
Am J Dermatopathol; 2007 Dec; 29(6):534-7. PubMed ID: 18032947
[TBL] [Abstract][Full Text] [Related]
15. Benign nodal nevi frequently harbor the activating V600E BRAF mutation.
Taube JM; Begum S; Shi C; Eshleman JR; Westra WH
Am J Surg Pathol; 2009 Apr; 33(4):568-71. PubMed ID: 19033861
[TBL] [Abstract][Full Text] [Related]
16. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.
Mudaliar K; Tetzlaff MT; Duvic M; Ciurea A; Hymes S; Milton DR; Tsai KY; Prieto VG; Torres-Cabala CA; Curry JL
Hum Pathol; 2016 Apr; 50():79-89. PubMed ID: 26997441
[TBL] [Abstract][Full Text] [Related]
17. Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites.
Cohen Y; Rosenbaum E; Begum S; Goldenberg D; Esche C; Lavie O; Sidransky D; Westra WH
Clin Cancer Res; 2004 May; 10(10):3444-7. PubMed ID: 15161700
[TBL] [Abstract][Full Text] [Related]
18. Melanocytic nevi and melanoma: unraveling a complex relationship.
Damsky WE; Bosenberg M
Oncogene; 2017 Oct; 36(42):5771-5792. PubMed ID: 28604751
[TBL] [Abstract][Full Text] [Related]
19. Improving classification of melanocytic nevi: Association of BRAF V600E expression with distinct histomorphologic features.
Kiuru M; Tartar DM; Qi L; Chen D; Yu L; Konia T; McPherson JD; Murphy WJ; Fung MA
J Am Acad Dermatol; 2018 Aug; 79(2):221-229. PubMed ID: 29653212
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA
Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
